{
  "abstract": "Background\n\nPsoriasis is a prevalent immune-mediated inflammatory skin disease. Deucravacitinib, an oral selective allosteric tyrosine kinase 2 (TYK2) inhibitor, provides a novel therapeutic option, but real-world data on its short-term efficacy, safety, and predictors of response among Chinese patients remain limited.Objective\n\nTo evaluate the 12-week efficacy, safety, and predictors of response to deucravacitinib in Chinese patients with moderate-to-severe plaque psoriasis in a real-world setting.Methods\n\nThis prospective, single-center cohort study enrolled 120 adult patients with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index ≥10, body surface area ≥10%, or Dermatology Life Quality Index ≥10) at a tertiary hospital in Shanghai, China. All patients received oral deucravacitinib 6 mg once daily for 12 weeks.Results\n\nAmong the 120 patients (mean age, 37.2 years; 58.3% male), the week 12 PASI 75, PASI 90, and PASI 100 response rates were 59.6%, 24.0%, and 4.8%, respectively. Regional PASI 75 response rates were highest for the head and neck (79%), followed by the trunk (76%), lower limbs (74%), and upper limbs (72%). Baseline body mass index <24 kg/m² independently predicted higher PASI 90 achievement (odds ratio, 5.34; 95% CI, 1.28-22.21), but was not associated with PASI 75. Exploratory comparisons showed that PASI 75 non-responders had higher baseline levels of TNF-α, IL-1β, IL-23p19, IFN-γ, and G-CSF in exploratory comparisons, with no differences in other Th1, Th2, Th17, or regulatory T-cell cytokines. Adverse events occurred in 41 of 120 patients (34.2%); the most common events were acne (24/120, 20.0%), folliculitis (13/120, 10.8%), and upper respiratory tract infection (7/120, 5.8%), and most were mild to moderate.Conclusion\n\nIn this real-world study, deucravacitinib was associated with significant clinical improvement over 12 weeks and had a favorable safety profile in Chinese patients with moderate-to-severe psoriasis, including improvement in difficult-to-treat anatomical regions. Baseline body mass index <24 kg/m² and lower pretreatment levels of proinflammatory cytokines were associated with better treatment responses.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 12,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Canbin Dong",
      "orcid": "0000-0001-9735-0661"
    },
    {
      "affs": [
        0
      ],
      "name": "Yilun Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "Jiazheng Sun"
    },
    {
      "affs": [
        0
      ],
      "name": "Jui-Ming Lin",
      "orcid": "0000-0003-4394-8873"
    },
    {
      "affs": [
        0
      ],
      "name": "Xiaonian Lu"
    },
    {
      "affs": [
        0
      ],
      "name": "Junhao Zhu"
    },
    {
      "affs": [
        0
      ],
      "name": "Lanmei Lin"
    },
    {
      "affs": [
        0
      ],
      "name": "Xinyi Zhu"
    },
    {
      "affs": [
        0
      ],
      "name": "Huiyu Huang"
    },
    {
      "affs": [
        0
      ],
      "name": "Jinhua Xu"
    },
    {
      "affs": [
        0
      ],
      "name": "Wenyu Wu"
    },
    {
      "affs": [
        0
      ],
      "name": "Juan Du",
      "orcid": "0000-0002-1327-820X"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/1s138qtfbv8k5.bib",
  "cited_by": 0,
  "doi": "10.2147/ptt.s647993",
  "fulltext_url": "https://europepmc.org/articles/PMC13702082",
  "id": "1s138qtfbv8k5",
  "issns": [
    "2230-326X"
  ],
  "landing_url": "https://europepmc.org/article/MED/42936288",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2403|Psoriasis: Treatment and Pathogenesis"
    ]
  ],
  "openalex": "W7223186706",
  "pdf_url": "https://europepmc.org/articles/PMC13702082?pdf=render",
  "pmcid": "PMC13702082",
  "pmid": "42936288",
  "published": "2026-10-22",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/1s138qtfbv8k5.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:22:12Z",
      "native_id": "MED:42936288",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42936288"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2403|Psoriasis: Treatment and Pathogenesis",
      "subfield": "immunology"
    }
  ],
  "title": "Prospective Study of Efficacy, Safety, and Predictors of Response to Deucravacitinib in Chinese Patients with Moderate-to-Severe Plaque Psoriasis.",
  "title_text": "Prospective Study of Efficacy, Safety, and Predictors of Response to Deucravacitinib in Chinese Patients with Moderate-to-Severe Plaque Psoriasis.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:22:12Z",
  "url": "https://research.draconitic.com/paper/1s138qtfbv8k5",
  "venue": "Psoriasis (Auckland, N.Z.)",
  "versions": []
}